PAA

2.50%

20.5¢ pharmaust limited

PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-493

First 493 Last

Share
Profile

Follow
theoc

2,588 Posts.

1474

22/02/22

17:08

Post #: 59739419
Share

Originally posted by kpax: ↑

Hi All,

I have been doing some research with another HC member.

We may have found something that to date no one has quantified in the pharmacodynamics of MPL.

Now, we know that mTOR inhibition is the principle action in reducing B cell Lymphoma in canines.

What scientists don't know specifically is why.

We feel it is to do with the TLR receptors in the body. They are Toll Like Receptors that when activated causes a mutant B cell which then grows to be a tumour ( immune system mediated cancer) . TLR receptors are your first line of immune defence. I have posted before on the bodies response to SARS, to some people it is a minor type presentation of a flu, to others it's ICU. Dependant on the immune inflammatory response.

What is interesting is that if you cross reference MPL with TLR you will not find any data.

Onto SARS-Cov-2 , the TLR sub set 2 is a cytokines inflammatory process which causes the mortality and morbidity.

mTOR inhibitors mediate TLR-2.

If we can control TLR-2 over activation we have a definitive handle on this.

MPL is a fourth generation rapalog of Rapamycin . It has far less side effects of the first generations.

Ref : mTORC1 signalling controls TLR-2 mediated T cell activation by inducing Tirap expression. Imanishi 2021.

Ref : TLR-2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Zheng 2021

Ref : Toll like receptors in the pathogenesis of human B cell malignancies. Isaza-Correa 2014.

We believe there is a substantial link , initially I believed , that MPL had to do with cell cycle arrest on the GO phase of replication of the SARS-Cov-2 cell in the body , time changes so does knowledge.

This is one awesome drug to study and I own a part of it. So do you. Happy days ahead.

Expand

Hi kpax. Mny tks for that. Have also been doing a spot or reading regards rapAmy in n mpl generally. Well above my pay grade. I'm not intending to cross promote but wondered if you have or could pls take a look at the imugene imu b cell platform n advice if you see any synergy as a pre/co-treatment or whether i am completely up the wrong path. Really appreciate feedback.

PAA Price at posting: 9.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

There are more pages in this discussion • 974 more messages in this thread...

First 493 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 20.5¢		Change 0.005(2.50%)		Mkt cap ! $99.71M

Open	High	Low	Value	Volume
20.5¢	20.5¢	20.0¢	$66.86K	327.5K

Buyers (Bids)

No.	Vol.	Price($)
3	27750	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
20.5¢	84999	3

View Market Depth

No.	Vol.	Price($)
3	27750	0.200
3	167702	0.195
4	192741	0.190
5	139546	0.185
6	264330	0.180

Price($)	Vol.	No.
0.205	84999	3
0.210	262500	5
0.215	261982	8
0.220	679543	10
0.225	592637	3

Last trade - 14.42pm 27/09/2024 (20 minute delay)

PAA (ASX) Chart

PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-493

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-493

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News